Management of<i>Helicobacter pylori</i>infection

Costa, Francesco; D’Elios, Mario Milco

doi:10.1586/eri.10.75

Cited by 8 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, based on reported data, the significant different eradication rate in this study represents the antibiotic resistance difference in different cities. The result might be interpreted and recommended with cautious in different cities Thirdly, tests for H. pylori are recommended multiple ways besides urea breath test, like stool test and serology for indirect tests, and histology, culture, real‐time PCR for direct tests . Single test might reduce the accuracy of H. pylori detection.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial

Liang

Han

et al. 2012

Helicobacter

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial

Liang

Han

et al. 2012

Helicobacter

View full text Add to dashboard Cite

show abstract

“…Traditionally, combination treatments are created by combining standard of care compounds in a hypothesis-driven manner. For example, two or more antibiotics targeting the same class of bacteria may be mixed, or an antibiotic may be combined with a resistance inhibitor . This method will not uncover unanticipated interactions between targets not thought to be mechanistically linked, and sometimes such rational designs may fail to be empirically confirmed .…”

mentioning

confidence: 99%

Parsimonious Discovery of Synergistic Drug Combinations

Severyn¹,

Liehr²,

Wolicki³

et al. 2011

ACS Chem. Biol.

View full text Add to dashboard Cite

Combination therapies that enhance efficacy or permit reduced dosages to be administered have seen great success in a variety of therapeutic applications. More fundamentally, the discovery of epistatic pathway interactions not only informs pharmacologic intervention but can be used to better understand the underlying biological system. There is, however, no systematic and efficient method to identify interacting activities as candidates for combination therapy and, in particular, to identify those with synergistic activities. We devised a pooled, self-deconvoluting screening paradigm for the efficient comprehensive interrogation of all pairs of compounds in 1000-compound libraries. We demonstrate the power of the method to recover established synergistic interactions between compounds. We then applied this approach to a cell-based screen for anti-inflammatory activities using an assay for lipopolysaccharide/interferon-induced acute phase response of a monocytic cell line. The described method, which is >20 times as efficient as a naïve approach, was used to test all pairs of 1027 bioactive compounds for interleukin-6 suppression, yielding 11 pairs of compounds that show synergy. These 11 pairs all represent the same two activities: β-adrenergic receptor agonists and phosphodiesterase-4 inhibitors. These activities both act through cyclic AMP elevation and are known to be anti-inflammatory alone and to synergize in combination. Thus we show proof of concept for a robust, efficient technique for the identification of synergistic combinations. Such a tool can enable qualitatively new scales of pharmacological research and chemical genetics.

show abstract

“…This persistent colonization has been linked to gastric ulcers, gastric adenocarcinoma [1], and mucosa‐associated lymphoid tissue lymphoma [2]. As a result of these serious consequences, currently most treatment protocols for peptic ulcer disease (PUD) include eradication of H. pylori as part of their regimens [3]. However, colonization with H. pylori can go undetected for decades and may have some early‐in‐life benefits [4,5]; how H. pylori are able to persist within the host for such long periods is not clearly understood.…”

mentioning

confidence: 99%

Genotypic and Phenotypic Variation of Lewis Antigen Expression in Geographically Diverse Helicobacter pylori Isolates

et al. 2011

View full text Add to dashboard Cite

Background Helicobacter pylori is a persistent colonizer of the human gastric mucosa, which can lead to the development peptic ulcer disease and gastric adenocarcinomas. However, H. pylori can asymptomatically colonize a host for years. One factor that has been hypothesized to contribute to such persistence is the production of Lewis (Le) antigens in the lipopolysaccharide layer of the bacterial outer membrane as a form of molecular mimicry, since humans also express these antigens on their gastric mucosa. Humans and H. pylori both are polymorphic for Le expression, which is driven in H. pylori by variation at the Le synthesis loci. In this report we sought to characterize Le genotypic and phenotypic variation in geographically diverse H. pylori isolates. Materials and Methods From patients undergoing endoscopy in 29 countries, we determined Le phenotypes of 78 H. pylori strains, and performed genotyping of the galT and β-(1,3)galT loci in 113 H. pylori strains. Results Le antigen phenotyping revealed a significant (p <0.0001) association between type 1 (Lea and Leb) expression and strains of East-Asian origin. Genotyping revealed a significant correlation between strain origin and the size of the promoter region upstream of the Le synthesis gene, galT (p <0.0001). Conclusion These results indicate that the heterogeneity of human Le phenotypes are reflected in their H. pylori colonizing strains, and suggest new loci that can be studied to assess variation of Le expression.

show abstract

Management ofHelicobacter pyloriinfection

Cited by 8 publications

References 41 publications

Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial

Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial

Parsimonious Discovery of Synergistic Drug Combinations

Genotypic and Phenotypic Variation of Lewis Antigen Expression in Geographically Diverse Helicobacter pylori Isolates

Contact Info

Product

Resources

About